Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Labour Govt Would Boost Health Spending, Put Pressure On Drug Prices

Out Goes R&D Credit, In Comes Compulsory Licensing

Executive Summary

The election manifesto produced by the Labour Party offers something for everyone, from the dropping of prescription charges and a boost for health care spending to more use of compulsory licensing and the building of a state-owned generics factory to make medicines more affordable.

You may also be interested in...



UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

UK Conservatives Promise ‘Innovative Medicines Fund’ If Re-Elected

More money to pay for innovative new medicines, more cash and support for the life sciences sector, and Brexit by 31 January 2020 are among promises made in the Conservative Party’s election platform. 

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel